TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22729212
Drug: Low-dose NRT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NRT (20.8 mg for 8 weeks)
Study: 25946654
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin (5 mg)
Study: 18294500
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin (40/80 mg)
Study: 18975103
Drug: Galantamine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16 mg/day)
Study: 2644747
Drug: Midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.075 mg/kg i.v.
Study: 811427
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (sublingual or oral)
Study: 28732453
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (sunitinib, pazopanib, axitinib, sorafenib)
Study: 28732453
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events of special interest treatment (pharmacologic and/or nonpharmacologic)
Study: 28732453
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor dose management
Study: 28732453
Drug: Neither treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither treatment nor dose management
Study: 28732453
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for fatigue
Study: 16521844
Drug: GEL
Normalized name: Gel
DrugBank: Sepia esculenta bone (DB16562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL
Study: 30753355
Drug: Control (Nongametocytocidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Nongametocytocidal drugs)
Study: 25155992
Drug: Carboxymethylcellulose (CMC)
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethylcellulose (CMC) (16 g total fiber/day)
Study: 25155992
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (GA) (16 g total fiber/day)
Study: 20610931
Drug: Posaconazole 200
Normalized name: posaconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 200 mg per os TID
Study: 9833600
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once daily for 6 weeks
Study: 9833600
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily for 6 weeks
Study: 8026247
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide 10 mg intravenously over 3 min
Study: 2596070
Drug: Antioxidant complex
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant complex (vitamins C, E, and A) administered preoperatively
Study: 335687
Drug: Pindolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2 X 2 tablets per 5 mg daily) and Trichlormethiazidum (1 X 1 tablet per 4 mg daily)
Study: 28856858
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment with SonoVue at 1 minute after administration
Study: 28856858
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment only (control group)
Study: 26324372
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg once per day for 2 years
Study: 23490328
Drug: ESBA105 6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESBA105 6.4 mg (cohort III)
Study: 23490328
Drug: ESBA105 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESBA105 3.2 mg (cohorts II and IV)
Study: 15213563
Drug: 2-dose intra-partum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose intra-partum nevirapine in combination with standard antiretroviral therapy
Study: 30408810
Drug: Low-salt (LS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt (LS) diet (3.0 g/day of NaCl)
Study: 30408810
Drug: High-salt (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt (HS) diet (18.0 g/day of NaCl)
Study: 26526662
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 diabetes with albuminuria (≥ 30 mg/24 h)
Study: 26526662
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 diabetes with normoalbuminuria (<30 mg/24 h)
Study: 22103428
Drug: Tramadol-lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-lidocaine (1 mg kg(‐1) and 2.46 mg kg(‐1))
Study: 20602575
Drug: exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise plus paroxetine 40 mg/day (n=21)
Study: 20602575
Drug: exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise plus pill placebo (n=20)
Study: 19952830
Drug: Water trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water trial (500 mL of plain water)
Study: 19952830
Drug: Bar trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar trial (commercially available energy bar with 10 µg of 19‐norandrostenedione)
Study: 18410769
Drug: aP (acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: aP (acellular pertussis vaccine)
Study: 18410769
Drug: HBV (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV (hepatitis B vaccine)
Study: 20064838
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received counseling, nicotine patches, quit guide, plus information about cigarette characteristics
Study: 20064838
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received counseling, nicotine patches, quit smoking guide
Study: 26015558
Drug: Behavioral Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Family Systems Therapy for Diabetes (BFST‐D)
Study: 12698207
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (10 mg daily)
Study: 9925870
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment with porcine surfactant (Curosurf)
Study: 8781630
Drug: Oral thyrotrophin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thyrotrophin-releasing hormone (TRH) and placebo
Study: 29479010
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target of < 2.07 mmol/L
Study: 20228381
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 or 100 mg)
Study: 12148173
Drug: Triamcinolone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (200 mcg twice daily)
Study: 2015731
Drug: Fluconazole, 200
Normalized name: Fluconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 200 mg orally, daily for 14 days
Study: 7278648
Drug: Mazindol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (1 mg, TID, po)
Study: 26743237
Drug: Delayed ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed ventricular tachycardia therapy programming (Arm C)
Study: 18767129
Drug: Combination recruitment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination recruitment (both reactive and proactive)
Study: 17660602
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF, or filgrastim) 300 mcg s/c weekly
Study: 10533795
Drug: UDCA (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (600 mg/day)
Study: 3524728
Drug: Sulphamethoxazole 2
Normalized name: Sulphamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphamethoxazole 2 g daily for 3 months
Study: 25230733
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin combined with Tiao Jing Cu Yun pills
Study: 22169113
Drug: MBX-8025 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBX-8025 (50 mg/d)
Study: 22169113
Drug: MBX-8025 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBX-8025 (100 mg/d)
Study: 17942379
Drug: Therapies evaluated
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies evaluated in trials
Study: 24195872
Drug: APAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP treatment for 2 or 3 preoperative nights and 5 postoperative nights.
Study: 21208974
Drug: RLY5016 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLY5016 (30 g/day)
Study: 31895058
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based treatment
Study: 31895058
Drug: Cognitive-behavioral usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral usual treatment
Study: 21429226
Drug: Non-professional mentor
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-professional mentor support (weekly home visiting for 12 months)
Study: 19646193
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (600 mg/day)
Study: 7530821
Drug: Oxy‐ or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy‐ or xylometazoline nasal spray for 30 days
Study: 3284831
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg piretanide once or twice daily
Study: 3294616
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide plus 5 mg amiloride once daily
Study: 28716617
Drug: Dignity Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity Therapy (DT) and Waitlist Dignity Therapy (WDT)
Study: 25801893
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen (IR) of cholecalcipherol (300,000 UI initial bolus followed by 50,000 UI monthly)
Study: 25801893
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (SR) of cholecalcipherol (25,000 UI monthly)
Study: 24061864
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered at 6:00
Study: 26093951
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered at 18:00
Study: 21568083
Drug: CCHT 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCHT 2 mg estradiol plus 1 mg norethisteron acetate
Study: 10662566
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine (PVP-I) in scrub formulation followed by alcoholic PVP-I
Study: 10662566
Drug: Chlorhexidine in
Normalized name: Product containing chlorhexidine in dental dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine in scrub formulation followed by alcoholic chlorhexidine
Study: 9305480
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 mg b.d.) + Omeprazole (20 mg b.d.)
Study: 9305480
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 mg b.d.) + Lansoprazole (30 mg b.d.)
Study: 9305480
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 mg b.d.) + Ranitidine (300 mg b.d.)
Study: 10899382
Drug: Mecamylamine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 5 mg
Study: 10899382
Drug: Mecamylamine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 10 mg
Study: 1410163
Drug: Mecamylamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (all doses)
Study: 3931138
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine at 2 mg every 2 hours
Study: 3931138
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine at lower doses
Study: 14999611
Drug: T-1249 monotherapy
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-1249 monotherapy (subcutaneous injection) at doses ranging from 6.25 to 192 mg/day for 14 days
Study: 9839758
Drug: Donepezil 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 4.0 mg
Study: 9839758
Drug: Donepezil 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 6.0 mg
Study: 21625083
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of hemodialysis at an estimated glomerular filtration rate (eGFR) of 5‐7 ml/min
Study: 10685792
Drug: Cyclosporine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (2.5 to 4 mg/kg/day) plus MTX
Study: 8088933
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate pharmacodynamics identification programme using a personal computer
Study: 3537785
Drug: Low-dose ketoconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ketoconazole, 100 mg daily for six months (Group C)
Study: 3537785
Drug: Low-dose ketoconazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketoconazole (Group C)
Study: 27380603
Drug: Ditto Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ditto Preparation and Distraction
Study: 17347975
Drug: i.v. L-propionyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. L-propionyl carnitine treatment for two months
Study: 12663237
Drug: Propranolol 40-120
Normalized name: propranolol hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40-120 mg/day
Study: 8290486
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (V/Z)
Study: 3728581
Drug: 100 gm
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 gm of oral glucose (group G)
Study: 26957102
Drug: Intravenous Patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Patient Controlled Analgesia (IV-PCA)
Study: 11199951
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with cognitive behavioral therapy
Study: 24399553
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg, 2 per day) with cognitive behavioral therapy
Study: 18436195
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1 g orally twice daily (b.i.d.)
Study: 1642682
Drug: Soluble ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble ibuprofen 200 mg sachets
Study: 1642682
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg tablets
Study: 1642682
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg tablets
Study: 12045491
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg
Study: 30977033
Drug: ADV 10
Normalized name: ADV-TK
DrugBank: Aglatimagene besadenovec (DB15074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV 10 mg
Study: 19580713
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue spray applied to the axillary fossa in 45 patients
Study: 19580713
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in 45 patients
Study: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
Normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-hydroxy-camptothecin (10-HCPT) 10 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Study: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
Normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-hydroxy-camptothecin (10-HCPT) 12 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Study: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
Normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-hydroxy-camptothecin (10-HCPT) 8 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Study: 9535618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitrate therapy)
Study: 6683976
Drug: Rectal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal absorption from aqueous solution
Study: 6683976
Drug: Rectal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal absorption from fatty suppository
Study: 6683976
Drug: Rectal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal absorption from alkaline solution containing codeine phosphate
Study: 6683976
Drug: Various rectal
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various rectal dosage forms
Study: 21613389
Drug: Computer-delivered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-delivered treatment (CDT)
Study: 19892281
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NTG)
Study: 16636488
Drug: valsartan plus
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: valsartan plus ACE inhibitor
Study: 10560360
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg, twice daily
Study: 10560360
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg, twice daily
Study: 2069791
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg or 180 mg twice daily
Study: 2069791
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg twice daily
Study: 2069791
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg twice daily
Study: 6840169
Drug: Sobrerol (mucolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sobrerol (mucolytic drug)
Study: 31595433
Drug: Ophthalmic 0.3%
Normalized name: ofloxacin ophthalmic 0.3% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic 0.3% gentamicin topical solution nightly for a 3-month period
Study: 21639808
Drug: vemurafenib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: vemurafenib (960 mg orally twice daily)
Study: 24508103
Drug: dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: dacarbazine (1000 mg/m² IV every 3 weeks)
Study: 20920276
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy with capecitabine (825 mg/m² twice daily during radiotherapy)
Study: 20920276
Drug: Preoperative combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combined therapy
Study: 18547150
Drug: 0.6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 18547150
Drug: 0.9 mL
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 18547150
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 15814754
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of ropivacaine 0.5%
Study: 15814754
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of ropivacaine 0.5%
Study: 15814754
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of ropivacaine 0.5%
Study: 12432177
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CM; 0.3 g kg d 1 + 20 g Polycose)
Study: 8613890
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (15 g dietary fiber)
Study: 26036554
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg) via patient-controlled epidural analgesia (PCEA)
Study: 9715842
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (40 mg/m2 every 2 weeks)
Study: 11099365
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (0.45% NaCl) equal to 50% of prior dehydration
Study: 2908820
Drug: ICI 118,551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551, 50 mg t.i.d.
Study: 2880804
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg t.i.d.
Study: 31444314
Drug: Collagen-containing supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-containing supplements (gelatin 20 g and hydrolyzed collagen 20 g)
Study: 31444314
Drug: Dairy protein
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy protein supplements (calcium caseinate 20 g and hydrolyzed casein 20 g)
Study: 28981381
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (180 mg EPA, 120 mg DHA) supplementation (1 g/day for 4 weeks)
Study: 23338256
Drug: 1% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% NaOCl solution
Study: 12398236
Drug: Hypoglycemic agents
Normalized name: HYPOGLYCEMIC AGENTS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic agents and/or diet